Stericycle Inc
SRCL: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$77.00 | Zqprwcb | Ttftthnb |
Stericycle's Q2 Featured Solid Organic Revenue Growth and Sequential Margin Improvement
Business Strategy and Outlook
Since its founding in 1989, Stericycle has been extremely acquisitive, having acquired over 500 companies. On the surface, this acquisitive strategy led to a lengthy period of impressive growth and the firm built unmatched scale. However, acquisitions began to stray from Stericycle's core competencies and poor integration efforts caused inefficiencies to build. After decades of strong growth and profitability, Stericycle's financial performance began to deteriorate in 2017.